ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
ACTU | US
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 1751 RIVER RUN, 76107 FORT WORTH
- Website:
- https://actuatetherapeutics.com/
- Sector:
- Manufacturing
Description
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies for cancers with high unmet medical needs. The company's lead drug candidate is elraglusib, a novel, first-in-class small molecule inhibitor of glycogen synthase kinase-3 (GSK-3). Elraglusib is being developed for difficult-to-treat cancers, including metastatic pancreatic cancer. Its mechanism of action targets multiple molecular pathways involved in promoting tumor growth and resistance to conventional drugs. Additionally, it functions as a mediator of anti-tumor immunity by inhibiting immune checkpoints and regulating immune cell function. The company's goal is to develop therapies that can slow, stop, or shrink tumors with minimal adverse effects, thereby improving patient outcomes.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ACTUATE THERAPEUTICS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ACTUATE THERAPEUTICS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ACTUATE THERAPEUTICS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
